Federal Register Notices > Notice of Application 2004 > Lin Zhi International, Inc.

Information and Legal Resources Banner

Notice of Application - 2004


FR Doc 04-5778 [Federal Register: March 15, 2004 (Volume 69, Number 50)] [Notices] [Page 12179] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr15mr04-106]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 20, 2004, Lin Zhi International, Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

Drug  Schedule 
Tetrahydrocannabinols (7370) I
3,4-Methylenedioxymethamphetamine (7405) I
Amphetamine (1100) II
Methamphetamine (1105) II
Secobarbital (2315) II
Phencyclidine (7471) II
Benzoylecgonine (9180) II
Cocaine (9041) II
Methadone (9250) II
Dextropropoxyphene (9273) II
Morphine (9300) II

The firm plans to manufacture small quantities of controlled substances to make drug testing reagents and controls. 

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration. 

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than May 14, 2004.

Dated: March 5, 2004. 

William J. Walker, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. 

[FR Doc. 04-5778 Filed 3-12-04; 8:45 am]

BILLING CODE 4410-09-M

NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO).

DEA: Drug Enforcement Administration Home